BioSpace News Archive

MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy Independent Third-Party Firm, Led by Former Senior FDA Officials, Calls Phase 2b Trial “Well-designed” and “Essential” Report Further Demonstrates that FCM’s Proposal to Skip Phase 2 for MM-120 – a Cornerstone of its Plan – is Unrealistic and Would Put MindMed Shareholders’ Investments at Risk Visit www.ProtectMindMed.com for More Information NEW YOR

Cartography Biosciences, an immuno-oncology company creating biologic therapies against novel targets guided by the first-ever comprehensive antigen atlas, announced the appointment of Blaine Templeman as Chief Administrative and Legal Officer.

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the acceptance of a late-breaking oral presentation for its lead product candidate RenovoGem, in the treatment of locally advanced pancreatic cancer (LAPC), at the upcoming ESMO World Congress on Gastrointestinal Cancer (ESMO GI).

Jaguar Health, Inc. (Nasdaq:JAGX) (“Jaguar” or the “Company”) today announced that the Company has successfully over-enrolled its global, pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy.

Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced that the Company’s intellectual property portfolio made important advancements in Europe.

Indee Labs announces an exclusive marketing and distribution deal with Sunko Instruments in China for Hydropore Research Use Only.

Brain Cancer Canada, a leading charity in the fight against brain cancer, is delighted to announce a $50,000 research grant to Dr. Amit Singnurkar at Sunnybrook Health Sciences Centre.

On May 19, 2023, Krystal Biotech, a client of Berkshire Sterile Manufacturing (BSM), received FDA approval for VYJUVEK™, the first-ever topical gene therapy approved to treat dystrophic epidermolysis bullosa (DEB) in children and adults six months of age or older.

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that all proposed resolutions submitted to the Annual General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST.

The Combined General Shareholders’ Meeting of Sanofi was held on May 25, 2023, under the chairmanship of Serge Weinberg.